Abstract 4654
Background
Splenic marginal zone lymphoma (SMZL) is a rare B-cell malignancy, with no standard treatment other than splenectomy. The aim of this retrospective single-center study was to evaluate the clinical characteristics and prognosis of SMZL.
Methods
Between 2008 and 2015, we analyzed a total of 52 patients being considered as appropriate diagnostic criteria for SMZL in our hematology clinic. There were 36 (69%) female and 16 (31%) male patients. Median age was 58.8 years (range, 37-88 years). The median time of follow-up was 20.3 months (range, 3-97.7 months).
Results
We retrospectively assessed 52 patients from single center, who received splenectomy, either alone or with chemotherapy. The presence of splenomegaly (95.2%) was recorded as the most frequent symptom at diagnosis. Of the patients, 44 (84.6%) had bone marrow involvement and 11 (21.2%) had lymph nodes involvement. Tumor involvement of peripheral blood defined as the presence of absolute lymphocytosis or 5% of tumor lymphocytes in peripheral blood was detected in 10 patients (19.2%). Because of the high frequency of bone marrow involvement, most patients in the series were Ann Arbor stage IV. Data concerning the presence of hypogammaglobulinemia was obtained from only 9 patients (42.9%). Obviously, 20 patients underwent splenectomy. In 7 patients (35%) chemotherapy was received apart from splenectomy.The number of patients reaching clinical complete remission after splenectomy with/out therapy was 18 (90%) and partial remission 3 (15%). The probability of 5 year-overall survival was 87.5%±11.7%. When we analyzed the patients with splenectomy alone the probability of overall survival was 83.3%±15.2%.
Conclusions
In conclusion, although the options of new treatment modality in SMZL have been debated today, splenectomy seems to be safe and effective in controlling long-term disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3020 - Circulating tumor DNA (ctDNA) analysis depicts mechanisms of resistance and tumor response to BRAF inhibitors in BRAF-mutant non-small cell lung cancer (NSCLC)
Presenter: Sandra Ortiz - Cuaran
Session: Poster Display session 1
Resources:
Abstract
1271 - A large scale prospective concordance study of oncogene driver detection between plasma- and tissue-based NGS analysis in advanced non-small cell lung cancer (NSCLC).
Presenter: Ryo Itotani
Session: Poster Display session 1
Resources:
Abstract
1132 - Biomarker status as a mediator of age-related overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
Presenter: Aaron Cohen
Session: Poster Display session 1
Resources:
Abstract
1502 - An exploratory analysis of on-treatment ctDNA measurement as a potential surrogate for overall survival for atezolizumab benefit in the OAK Study
Presenter: David Gandara
Session: Poster Display session 1
Resources:
Abstract
3912 - Disease monitoring of EGFR mutation-positive NSCLC patients via circulating tumor DNA
Presenter: Wei Fang Hsu
Session: Poster Display session 1
Resources:
Abstract
3856 - Incidence of T790M in NSCLC patients progressed to gefitinib, erlotinib, and afatinib: a study on circulating tumor DNA
Presenter: Romano Danesi
Session: Poster Display session 1
Resources:
Abstract
1330 - Folate receptor-positive circulating tumor cells as a predictive biomarker for the efficacy of first-line pemetrexed-based therapy in patients with non-squamous non-small cell lung cancer
Presenter: Xiaoxia Chen
Session: Poster Display session 1
Resources:
Abstract
3512 - Carcinoembryonic Antigen of Cerebrospinal Fluid Predict Prognosis of Leptomeningeal Metastasis from Non-Small Cell Lung Cancer
Presenter: Junjie Zhen
Session: Poster Display session 1
Resources:
Abstract
3852 - Liquid biopsy in clinical pratice of Non-Small-Cell-Lung Cancer (NSCLC): a multi-institutional experience
Presenter: Giovanna De Maglio
Session: Poster Display session 1
Resources:
Abstract
1205 - A Phase III Study Comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC
Presenter: Martin Reck
Session: Poster Display session 1
Resources:
Abstract